Memorial Sloan Kettering Cancer Center Issues Statement on the First Quarter of 2024 Financial Results


Memorial Sloan Kettering Cancer Center (MSK) issued the following statement regarding its first quarter of 2024 results:  

“MSK’s financial performance for the first quarter of 2024 continued to demonstrate positive financial results with an operating income of $28.1 million. These operating results are attributed to our ongoing financial recovery plans, expense management, and continued clinical growth. 

We achieved an operating cash flow margin of 5.7% due to strong growth in clinical, research and philanthropy activity, in addition to sound expense management. Patient revenues increased by 14.7% compared to the first quarter of 2023, while total operating expenses rose just 9.0% in support of additional patient activity. 

MSK remains on a stable financial trajectory and continues to execute a fiscal strategy that anticipates the judicious use of reserves as margins improve over the long-term. We remain optimistic that ongoing initiatives to expand patient access and manage expenses will lead to continued improvement in operating results.”

For more information, please see instructions to access our financial disclosure report available at or